Sökning: "E Niclas Jonsson"

Hittade 5 avhandlingar innehållade orden E Niclas Jonsson.

1. 1. Benefits of Pharmacometric Model-Based Design and Analysis of Clinical Trials

   Författare :Kristin E Karlsson; E Niclas Jonsson; Mats O Karlsson; Anders Grahnén; Michael K Smith; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; model-based analysis; pharmacometrics; modeling; disease progression; NONMEM; SAEM; Importance sampling; repeated time-to-event; RTTCE; RCEpT; NIH stroke scale; Barthel index; internal validation; external validation; study power; study design; PHARMACY; FARMACI; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

   Sammanfattning : Quantitative pharmacokinetic-pharmacodynamic and disease progression models are the core of the science of pharmacometrics which has been identified as one of the strategies that can make drug development more effective. To adequately develop and utilize these models one needs to carefully consider the nature of the data, choice of appropriate estimation methods, model evaluation strategies, and, most importantly, the intended use of the model. LÄS MER

3. 2. Pharmacometric Models for Individualisation of Warfarin in Adults and Children

   Författare :Anna-Karin Hamberg; Mia Wadelius; E Niclas Jonsson; Lena E Friberg; Jeffrey S Barrett; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; warfarin; pharmacokinetics; pharmacodynamics; pharmacometrics; pharmacogenetics; dose individualisation; children; Klinisk farmakologi; Clinical Pharmacology;

   Sammanfattning : Warfarin is one of the most widely used anticoagulants. Therapy is complicated by warfarin’s narrow therapeutic range and pronounced variability in individual dose requirements. Although warfarin therapy is uncommon in children, it is crucial for children with certain congenital or acquired heart diseases. LÄS MER

4. 3. Methodological studies on non-linear mixed effects model building

   Författare :E. Niclas Jonsson; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacy; FARMACI; PHARMACY; FARMACI; Biopharmaceutics; biofarmaci;

   Sammanfattning : Population analysis of pharmacokinetic/pharmacodynamic (PK/PD) data by the use of non-linear mixed effects modeling offers a number of benefits over traditional methods of analyzing this type of data. These benefits include the possibility to appropriately characterize the typical PK/PD behaviour in the population as well as the associated variability when only a few observations are available for each individual. LÄS MER

5. 4. Role of the Blood-Brain Barrier in Stereoselective Distribution and Delay in H1 Receptor Occupancy of Cetirizine in the Guinea Pig Brain

   Författare :Anubha Gupta; Margareta Hammarlund-Udenaes; Niclas E. Jonsson; Joseph W. Polli; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacokinetics Pharmacotherapy; Cetirizine enantiomers; Brain distribution; Microdialysis; H1 receptor occupancy; Stereoselective-pharmacokinetics; Farmakokinetik Farmakoterapi; PHARMACY; FARMACI;

   Sammanfattning : Cetirizine, an H1-antihistamine, is prescribed for allergic disorders. It exists as a racemic mixture, with levocetirizine being the active enantiomer. The central nervous system side-effects of H1-antihistamines are caused by their penetration into the brain. LÄS MER

7. 5. Models for Ordered Categorical Pharmacodynamic Data

   Författare :Per-Henrik Zingmark; Mats O Karlsson; E. Niclas Jonsson; France Mentré; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacokinetics Pharmacotherapy; Pharmacodynamic; Modelling; Categorical data; NONMEM; Proportional odds model; Markov model; Differential drug effect model; Farmakokinetik Farmakoterapi; PHARMACY; FARMACI;

   Sammanfattning : In drug development clinical trials are designed to investigate whether a new treatment is safe and has the desired effect on the disease in the target patient population. Categorical endpoints, for example different ranking scales or grading of adverse events, are commonly used to measure effects in the trials. LÄS MER